Fig. 2.

Molecular outcome. Evolution of genetic clones, as measured by targeted NGS, together with the percentage of bone marrow blasts and cytogenetic profile for patients 1–5(a–e). Missing data for cytogenetics is due to poor sample quality or because the cytogenetic analysis was not performed. P4 did not have clinical progression at the first evaluation time point and was consequently re-evaluated later, showing progression to AML